Next Article in Journal
Characterization of HGF/Met Signaling in Cell Lines Derived From Urothelial Carcinoma of the Bladder
Next Article in Special Issue
Exploring the Mechanisms of Gastrointestinal Cancer Development Using Deep Sequencing Analysis
Previous Article in Journal
Clinicopathologic Characteristics and Outcomes of Histiocytic and Dendritic Cell Neoplasms: The Moffitt Cancer Center Experience Over the Last Twenty Five Years
Open AccessReview

Next-Generation Sequencing in Clinical Oncology: Next Steps Towards Clinical Validation

1
The University of Queensland, UQ Centre for Clinical Research, Herston Qld 4029, Australia
2
The Australian Centre for Oral Oncology Research & Education, Brisbane Qld 4000, Australia
*
Author to whom correspondence should be addressed.
Cancers 2014, 6(4), 2296-2312; https://doi.org/10.3390/cancers6042296
Received: 11 October 2014 / Revised: 7 November 2014 / Accepted: 10 November 2014 / Published: 18 November 2014
(This article belongs to the Special Issue Next Generation Sequencing Approaches in Cancer)
Compelling evidence supports the transition of next generation sequencing (NGS) technology from a research environment into clinical practice. Before NGS technologies are fully adopted in the clinic, they should be thoroughly scrutinised for their potential as powerful diagnostic and prognostic tools. The importance placed on generating accurate NGS data, and consequently appropriate clinical interpretation, has stimulated much international discussion regarding the creation and implementation of strict guidelines and regulations for NGS clinical use. In the context of clinical oncology, NGS technologies are currently transitioning from a clinical research background into a setting where they will contribute significantly to individual patient cancer management. This paper explores the steps that have been taken, and those still required, for the transition of NGS into the clinical area, with particular emphasis placed on validation in the setting of clinical oncology. View Full-Text
Keywords: massively parallel sequencing; next generation sequencing; clinical oncology; validation massively parallel sequencing; next generation sequencing; clinical oncology; validation
Show Figures

Figure 1

MDPI and ACS Style

Bennett, N.C.; Farah, C.S. Next-Generation Sequencing in Clinical Oncology: Next Steps Towards Clinical Validation. Cancers 2014, 6, 2296-2312. https://doi.org/10.3390/cancers6042296

AMA Style

Bennett NC, Farah CS. Next-Generation Sequencing in Clinical Oncology: Next Steps Towards Clinical Validation. Cancers. 2014; 6(4):2296-2312. https://doi.org/10.3390/cancers6042296

Chicago/Turabian Style

Bennett, Nigel C.; Farah, Camile S. 2014. "Next-Generation Sequencing in Clinical Oncology: Next Steps Towards Clinical Validation" Cancers 6, no. 4: 2296-2312. https://doi.org/10.3390/cancers6042296

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Search more from Scilit
 
Search
Back to TopTop